Table 4.
Summary of Results for Selected Studies Utilizing EUS-Guided EA for pNET Therapy.
| Author | Study Year | Ablative Strategy | Number of Treated Patients | Number of Treated Lesions | Efficacy on Follow-Up Imaging *, n (%) | Adverse Events, (n) | ||
|---|---|---|---|---|---|---|---|---|
| Insulinoma | Non-Functional pNET | Incomplete Response | Complete Response | |||||
| Levy et al. [69] | 2012 | Ethanol (95–99%) | 5 | 5 | 0 | N/A ** | N/A ** | None |
| Park et al. [31] | 2015 | Ethanol (99%) | 11 | 4 | 10 | 5 (38) | 8 (62) | Mild abdominal pain (1); Acute pancreatitis (3); MPD stricture (1) |
| Choi et al. [70] | 2018 | Ethanol (99%) + Lipiodol | 33 | 1 | 39 | 16 (40) | 24 (60) | Acute pancreatitis (2) |
| Matsumoto et al. [71] | 2020 | Ethanol | 5 | 0 | 5 | 1 (20) | 4 (80) | None |
* Complete response is defined as the radiographic absence of residual lesion on post-procedural imaging. Incomplete response is defined as either persistent or enlarged residual lesion on post-procedural imaging. ** No follow-up imaging was obtained to assess therapeutic efficacy, although 3 of 5 patients reported post-procedural resolution of hypoglycemic symptoms.